Incidence and Prognostic Significance of HER-2 Status Discordance Between Primary Breast Cancer and Paired Recurrent/Metastatic Lesions
CompletedOBSERVATIONAL
Enrollment
1,299
Participants
Timeline
Start Date
January 1, 2021
Primary Completion Date
June 1, 2022
Study Completion Date
June 1, 2022
Conditions
Breast Cancer
Interventions
OTHER
no intervention
no intervention was needed
Trial Locations (1)
Unknown
Fudan University Shanghai Cancer Center, Shanghai
All Listed Sponsors
lead
Fudan University
OTHER
NCT05510037 - Incidence and Prognostic Significance of HER-2 Status Discordance Between Primary Breast Cancer and Paired Recurrent/Metastatic Lesions | Biotech Hunter | Biotech Hunter